Edition:
United States

Glaukos Corp (GKOS.N)

GKOS.N on New York Stock Exchange

40.61USD
13 Aug 2018
Change (% chg)

$-1.34 (-3.19%)
Prev Close
$41.95
Open
$41.83
Day's High
$41.83
Day's Low
$40.48
Volume
86,525
Avg. Vol
117,696
52-wk High
$46.50
52-wk Low
$23.10

Latest Key Developments (Source: Significant Developments)

Glaukos Q4 Earnings Per Share $0.03
Wednesday, 28 Feb 2018 04:10pm EST 

Feb 28 (Reuters) - Glaukos Corp ::ORATION ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.03.SEES FY 2018 SALES $160 MILLION TO $165 MILLION.Q4 SALES ROSE 26 PERCENT TO $41.7 MILLION.Q4 EARNINGS PER SHARE VIEW $0.01, REVENUE VIEW $41.1 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $169.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort
Wednesday, 10 Jan 2018 07:00am EST 

Jan 10 (Reuters) - Glaukos Corp ::GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT.GLAUKOS CORP - COMPANY PREPARES TO COMMENCE PHASE III U.S. IND STUDY IN FIRST HALF OF 2018.GLAUKOS CORP - COMPANY BEGINS PROCESS FOR IDOSE TRAVOPROST REGULATORY APPROVAL IN EUROPE AND JAPAN.GLAUKOS CORP - CONDUCTED A PRODUCTIVE END-OF-PHASE II MEETING WITH FDA IN LATE 2017.  Full Article

Glaukos Submits IDE Application To FDA To Study iStent Infinite Trabecular Micro-Bypass System
Wednesday, 3 Jan 2018 07:00am EST 

Jan 3 (Reuters) - Glaukos Corp ::GLAUKOS SUBMITS IDE APPLICATION TO FDA TO STUDY ISTENT INFINITE™ TRABECULAR MICRO-BYPASS SYSTEM.GLAUKOS CORP - ‍SUBMITTED IDE APPLICATION TO FDA SEEKING AUTHORIZATION TO STUDY ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM​.  Full Article

Glaukos To Begin Randomized U.S. IDE Pivotal Clinical Trial For iStent SA System
Tuesday, 19 Dec 2017 07:00am EST 

Dec 19 (Reuters) - Glaukos Corp ::GLAUKOS TO BEGIN RANDOMIZED U.S. IDE PIVOTAL CLINICAL TRIAL FOR THE ISTENT SA™ SYSTEM.GLAUKOS SAYS U.S. FDA IS ALLOWING CO TO MOVE FORWARD WITH U.S. IDE PIVOTAL STUDY OF ITS ISTENT SA TRABECULAR MICRO-BYPASS SYSTEM.  Full Article

Glaukos Corp posts Q3 earnings per share $0.04
Tuesday, 7 Nov 2017 04:15pm EST 

Nov 7 (Reuters) - Glaukos Corp :Glaukos Corporation announces third quarter 2017 financial results.Q3 earnings per share $0.04.Q3 sales $40.4 million versus I/B/E/S view $39.1 million.Q3 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S.Sees FY 2017 sales $155 million to $160 million.  Full Article

James Flynn reports a 7.34 pct passive stake in Glaukos
Monday, 25 Sep 2017 05:56pm EDT 

Sept 25 (Reuters) - Glaukos Corp :James E. Flynn reports a 7.34 Pct passive stake in Glaukos Corp as of Sept 14 - SEC filing.  Full Article

Glaukos to outline growth strategy at investor day
Thursday, 14 Sep 2017 06:00am EDT 

Sept 14 (Reuters) - Glaukos Corp ::Glaukos to outline growth strategy at investor day.Glaukos Corp says ‍revises 2017 net sales guidance​.Glaukos Corp says ‍revising guidance for Q3 net sales to range of $38 million to $40 million​.Glaukos Corp says ‍revising its guidance for full year 2017 net sales to a range of $155 million to $160 million​.  Full Article

Glaukos Corporation Q2 loss per share $0.10
Wednesday, 2 Aug 2017 04:10pm EDT 

Aug 2 (Reuters) - Glaukos Corp :Glaukos Corporation announces second quarter 2017 financial results.Q2 loss per share $0.10.Q2 sales $41.3 million versus I/B/E/S view $39.7 million.Q2 earnings per share view $0.05 -- Thomson Reuters I/B/E/S.Sees FY 2017 sales $162 million to $167 million.Glaukos Corp - affirmed 2017 net sales guidance of $162 million to $167 million.Glaukos Corp - net sales rose 45% in Q2 of 2017 to $41.3 million.FY2017 revenue view $165.5 million -- Thomson Reuters I/B/E/S.  Full Article

Glaukos Corporation announces Q1 sales $35.9 million
Wednesday, 3 May 2017 04:15pm EDT 

May 3 (Reuters) - Glaukos Corp :Glaukos Corporation announces first quarter 2017 financial results.Q1 earnings per share $0.02.Q1 sales $35.9 million versus I/B/E/S view $33.7 million.Sees FY 2017 sales $162 million to $167 million.Q1 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S.Glaukos Corp - Raised 2017 net sales guidance to a range of $162 million to $167 million.Glaukos Corp - Revised guidance implies growth in 2017 net sales of approximately 42% to 46%, compared to 2016 net sales.FY2017 revenue view $163.5 million -- Thomson Reuters I/B/E/S.  Full Article

Glaukos completes patient enrollment in phase ii clinical trial for idose™ travoprost intraocular implant
Wednesday, 3 May 2017 07:00am EDT 

May 3 (Reuters) - Glaukos Corp ::Glaukos completes patient enrollment in phase ii clinical trial for idose™ travoprost intraocular implant in glaucoma patients.Glaukos corp- topline readout expected later in 2017 for study.  Full Article

BRIEF-Glaukos Q1 Loss Per Share $0.08

* GLAUKOS CORP ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS